Cargando…

Improved understanding of NSCLC immunotherapy response mechanisms from single-cell analysis

Detalles Bibliográficos
Autores principales:	Bienkowska, Kamila Justyna, Hanley, Christopher Jon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483077/ https://www.ncbi.nlm.nih.gov/pubmed/37691874 http://dx.doi.org/10.21037/tlcr-23-428

Ejemplares similares

Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
por: Monteverdi, Sara, et al.
Publicado: (2020)

Immunotherapy and NSCLC: The Long and Winding Road
por: Rossi, Antonio
Publicado: (2020)

One more step towards a deeper understanding of the mechanisms of allergen immunotherapy
por: Incorvaia, Cristoforo
Publicado: (2018)

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?
por: Morabito, Alessandro
Publicado: (2018)

Tissue MicroRNA Expression as a Predictor of Response to Immunotherapy in NSCLC Patients
por: Grenda, Anna, et al.
Publicado: (2021)

Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?
por: Moliner, L., et al.
Publicado: (2023)

Cancer-Associated Fibroblasts in Oral Cancer: A Current Perspective on Function and Potential for Therapeutic Targeting
por: Bienkowska, Kamila J., et al.
Publicado: (2021)

DNA methylation profiling in early lung adenocarcinoma to predict response to immunotherapy
por: De Smet, Charles
Publicado: (2023)

Making cytology specimens solid materials for testing predictive marker of immunotherapy in NSCLC
por: Wang, Hangjun, et al.
Publicado: (2018)

First-line immune-chemotherapy combination for squamous NSCLC is already a reality
por: Hendriks, Lizza E. L., et al.
Publicado: (2020)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

PET-Plan: potential for dose escalation by target volume reduction in locally advanced NSCLC
por: de Jong, Evelyn E. C., et al.
Publicado: (2020)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Single-cell insights into the dynamic tumor microenvironment changes during immunotherapy of non-small cell lung cancer
por: Prazanowska, Karolina Hanna, et al.
Publicado: (2023)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
por: Goh, Kah Yee, et al.
Publicado: (2023)

A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC
por: Del Re, Marzia, et al.
Publicado: (2020)

Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy
por: Shi, Yanhong, et al.
Publicado: (2023)

Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC
por: Strickland, Matthew R., et al.
Publicado: (2020)

Local treatment of synchronous oligometastatic non-small cell lung cancer (NSCLC)—current consensus and future perspectives
por: Almeldin, Doaa Said, et al.
Publicado: (2020)

Characterization of the tumor microenvironment by single-cell RNA sequencing in non-small cell lung cancer treated with neo-adjuvant immunotherapy
por: Nagl, Laurenz, et al.
Publicado: (2023)

The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
por: Brazel, Danielle, et al.
Publicado: (2023)

IMPassionate about immunotherapy for TNBC: from change, to revolution and to cure?
por: Vagia, Elena, et al.
Publicado: (2020)

Tarlatamab: the promising immunotherapy on its way from the lab to the clinic
por: Tang, Daolin, et al.
Publicado: (2023)

Single-Cell Landscape of Liver Cancer in Response to Immunotherapy
por: Diao, Feiyu
Publicado: (2021)

Meta-analysis of single agents in the chemotherapy of NSCLC: what do we want to know?
por: Bahl, A, et al.
Publicado: (2001)

Immunotherapy in cervical cancer: the advent of precision medicine
por: De Felice, Francesca, et al.
Publicado: (2020)

Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
por: De Marchi, Pedro, et al.
Publicado: (2023)

Depression in CKD: Understanding the Mechanisms of Disease
por: Shirazian, Shayan
Publicado: (2018)

Mechanisms Responsible for Metabolic Improvements of Bariatric Surgeries
por: Kirwan, John P., et al.
Publicado: (2018)

Oncolytic immunotherapy for metastatic cancer: lessons and future strategies
por: Guo, Zong-Sheng
Publicado: (2020)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice
por: Celsa, Ciro, et al.
Publicado: (2023)

The Landscape of Immunotherapy Resistance in NSCLC
por: Frisone, Daniele, et al.
Publicado: (2022)

Use of single-cell technology to improve our understanding of the role of TLR2 in macrophage–Mycobacterium tuberculosis interaction
por: Gouzy, Alexandre
Publicado: (2023)

Refining precision cancer therapy in ALK-positive NSCLC
por: Lin, Jessica J., et al.
Publicado: (2019)

The KEY for chemo-immunotherapy combination: taking NOTEs from squamous cell lung cancer
por: Reale, Maria Lucia, et al.
Publicado: (2020)

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
por: Russo, Alessandro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4kf3hfonoi94ds6fci7na3v5nc